RecruitingNot ApplicableNCT06891326

Efficacy and Safety of tACS for Depression: a Multicenter RCT Study

Efficacy and Safety of Transcranial Alternating Current Stimulation for Depression: a Multicenter Randomized Controlled Trial Study


Sponsor

Ruijin Hospital

Enrollment

72 participants

Start Date

Oct 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Transcranial alternating current stimulation (tACS) is a promising non-invasive technique for major depression, because of its advantage of lower risks and expenses compared to other therapies such as deep brain stimulation, electroconvulsive therapy, and repetitive transcranial magnetic stimulation. Randomized controlled trials (RCTs) of depression treated by tACS have been conducted but provided limited and incongruous results. We designed a multi-center RCT to evaluate the efficacy and safety of tACS for depression. Eligible participants will be patients diagnosed with depression (HDRS-17≥8), aged 18 to 65, and without other conditions that could interfere with the study. A total of 72 participants will be recruited from 4 clinic centers. Participants will be randomized 1:1 to active tACS or sham stimulation group. The study staff and the participants are blinded to the randomization results. Stimulating electrodes will be placed on the scalp corresponding to bilateral dorsolateral prefrontal cortex (DLPFC) using frequency of 10Hz and amplitude of 1.5 to 2.0 mA. The intervention will last for 4 weeks, containing 20 40-minute sessions in total. Another 4-week observation will be followed by the end of the intervention. Participants will receive assessments at baseline, 2 weeks, 4 weeks, 6 weeks, and 8 weeks after the study begins. Psychological scales are used for the evaluation of their mental and quality of life. Besides, electroencephalogram (EEG) recording and magnetic resonance imaging (MRI) scans will also be performed to quantitatively measure the neural activities as well as the functional connectivity changes within the depression-related circuits.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • Clinical diagnosis of depressive disorder;
  • Age ranges between 18 and 65 years;
  • HDRS-17 score equals to or above 8;
  • No medical history/Under stable antidepressant treatment in one month;

Exclusion Criteria4

  • Combination of other psychotic disorders and neurological diseases;
  • History of invasive brain surgeries;
  • Non-invasive neurostimulation treatments within 3 months;
  • Physical condition that may endanger patients' safety during the study.

Interventions

DEVICEsham transcranial Alternating Current Stimulation

we use fade-in, short-stimulation, fade-out (FSF) stimulation pattern, with 60s-long fade-in/out periods, 2.0mA peak current at the beginning and the end of stimulation session

DEVICEactive tACS

The active tACS protocol lasted for 40 min of continuous sine-wave stimulation with the frequency of 10Hz and an amplitude ranging from 1.5mA to 2.0mA, adjusted according to the tolerability among individuals.


Locations(2)

Ruijin Hospital affiliated to Shanghai JiaoTong University School of Medicine

Shanghai, China

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06891326


Related Trials